Skip to main content

Advertisement

SpringerLink
Log in

Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy

  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Clinical studies have shown a correlation of HER-2/neu amplification/over-expression and favorable response to neoadjuvant chemotherapy and anti-HER-2/neu antibody treatment. However, contradictory findings also have been reported. Some tumors may develop resistance to neoadjuvant chemotherapy after an initial period of sensitivity. Our study attempts to evaluate the effects of neoadjuvant chemotherapy on HER-2/neu status in locally advanced breast cancer.

Thirty-nine patients with locally advanced breast cancers established by core needle biopsy received neoadjuvant chemotherapy and were compared with 60 patients with breast cancers who did not receive neoadjuvant chemotherapy. IHC for HER-2/neu was performed on paraffin sections of the core biopsy before treatment and the excised specimen following chemotherapy and scored as Negative (0-1 + ), 2 + and 3+. The results of the study and the controls were compared and analyzed using Fisher’s exact test.

HER-2/neu IHC scores decreased in 28.5% (15/39) of patients receiving neo-adjuvant chemotherapy compared to 11.7% (7/60) of patients in the control (p> 0.013). HER-2/neu IHC status changed from strongly positive to negative (3+ to 0) in five of 39 (12.5%) in the study group and in 2 of 60 (3.3%) in con-trol group 0 = 0.104).

For patients receiving neoadjuvant chemotherapy in whom the tumor becomes refractory to chemotherapy or recurs, repeat testing for HER-2/neu status may be necessary. Elimination of HER-2/neu positive tumor cells may account for the changes in the IHC scores and the development of resistance to neoadjuvant chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A,McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene.Science 235:177–182,1987.

    Article  PubMed  CAS  Google Scholar 

  2. Hoff ER, Tubb RR, Myles JL, Procop GW: HER-2/neu amplification in breast cancer: stratification by tumor type and grade.Am J Clin Pathol 117:916–921, 2002.

    Article  PubMed  CAS  Google Scholar 

  3. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.Stem Cells 16:413–428,1998.

    Article  PubMed  CAS  Google Scholar 

  4. Wang J, Buchholz TA, Middleton LP,et al: Assessment histologic features and expression of biomarkers in predicting pathologic response to anthracy-cline-based neo-adjuvant chemotherapy in patients with breast carcinoma.Cancer 94:3107–3114,2002.

    Article  PubMed  CAS  Google Scholar 

  5. Paik S, Park C: HER-2 and choice of adjuvant chemotherapy in breast cancer.Semin Oncol 28:332–335,2000.

    Article  Google Scholar 

  6. Vogel CL, Cobleigh MA, Tripathy D,et al: Efficacy and safety of Trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer.J Clin Oncol 20:719–726, 2002.

    Article  PubMed  CAS  Google Scholar 

  7. Carter P, Presta L, Gorman CM,et al: Humanization of an anti-pl85HER2 antibody for human cancer therapy.Proc Natl Acad Sci USA 89:4285–4289,1992.

    Article  PubMed  CAS  Google Scholar 

  8. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ,School S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overex-pressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 17:2639–2648,1999.

    PubMed  CAS  Google Scholar 

  9. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-pl85HER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer.J Clon Oncol 14:737–744,1996.

    CAS  Google Scholar 

  10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2.N Engl J Med 344:783–792, 2001.

    Article  PubMed  CAS  Google Scholar 

  11. Cooke T, Reeves J, Lanigan A, Stanton P: HER2 as a prognostic and predictive marker for breast cancer.Ann Oncol 12 (suppl l):S23–28,2001.

    Article  PubMed  Google Scholar 

  12. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L: Correlation between HER-2/neu and response to neo-adjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.Cancer 97:1758–1765, 2003.

    Article  PubMed  CAS  Google Scholar 

  13. Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Busso-lati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against cerbB2 protein domains.Histopathology 43:354–362, 2003.

    Article  PubMed  CAS  Google Scholar 

  14. Cardoso F, Piccart MJ, Durbecq V, Di Leo A: Resistance to trastuzumab: a necessary evil or a temporary challenge?Clin Breast Cancer 3:247–257, 2002.

    Article  PubMed  CAS  Google Scholar 

  15. McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer over-expressing HER2.Drugs 62:209–243, 2002.

    Article  PubMed  CAS  Google Scholar 

  16. Yamauchi H, Stearns V, Hayes DF: The role of cerbB-2 as a predictive factor in breast cancer.Breast Cancer 8:171–183, 2001.

    Article  PubMed  CAS  Google Scholar 

  17. Lo SS, Wang HC, Shyr YM, Lui WY: Can hormone receptor status of primary breast cancer be altered by neo-adjuvant chemotherapy?J Surg Oncol 57:94–96,1994.

    Article  PubMed  CAS  Google Scholar 

  18. Lee SH, Chung MA, Quddus MR, Steinhoff MM, Cady B: The effect of neo-adjuvant chemotherapy on estrogen and progesterone receptor expression and hormone status in breast cancer.Am J Surg 348’350, 2003.

    Google Scholar 

  19. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirill F, Bolsi G, Bertoli, Alquati P, Dogliotti L: Effect of neo-adjuvant chemotherapy on Ki67 labeling index, c-erbB-2 expression and steroid hormone receptor status in human breast cancers.Anticancer Res 16:3105–3110,1996.

    PubMed  CAS  Google Scholar 

  20. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H: Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.Am J Clin Pathol 118:693–698,2002.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Women & Infants Hospital and Brown Medical School, Providence, Rhode Island, USA

    M. Ruhul Quddus, C. James Sung, Cunxian Zhang, Terese Pasqueriello, Meryle Eklund & Margaret M. Steinhoff

Authors
  1. M. Ruhul Quddus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. James Sung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cunxian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Terese Pasqueriello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meryle Eklund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Margaret M. Steinhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

BS (ASCP)

BS

Corresponding author

Correspondence to Margaret M. Steinhoff.

About this article

Cite this article

Quddus, M.R., Sung, C.J., Zhang, C. et al. Her-2/neu expression in locally advanced breast carcinomas: pre- and post-neoadjuvant chemotherapy. Breast Cancer 12, 294–298 (2005). https://doi.org/10.2325/jbcs.12.294

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.2325/jbcs.12.294

Keywords

Search

Navigation